Home » Topics » BioWorld Science

BioWorld Science
RSS

Lasmiditan for acute treatment of migraine: results from phase III trial

July 5, 2019

WDFY3 gene variants linked to mild to moderate neurodevelopmental delay and intellectual disability

July 5, 2019

FDA approves Xembify for primary immunodeficiencies

July 5, 2019

Innovate UK grant supports ROP cancer vaccine development

July 5, 2019

Pyramid Biosciences synthesizes NTRK1 inhibitors

July 5, 2019

REVOLUTION Medicines identifies PTPN11 inhibitors

July 5, 2019

Janssen Biotech patent describes hSTING agonists

July 5, 2019

Bristol-Myers Squibb patents TLR7, TLR8 and/or TLR9 antagonists

July 5, 2019

Aquaporin-1 is a potential therapeutic target in TBI, researchers find

July 5, 2019

SP-8356, a CD147 inhibitor, is a potential compound for treating atherosclerosis

July 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...